Amgen's PSCK9 shows rare disease potential

Share this article:
Amgen's PSCK9 shows rare disease potential
Amgen's PSCK9 shows rare disease potential

Amgen announced Monday another round of positive results for its experimental human monoclonal antibody evolocumab, part of the close PCSK9 race that includes competitors such as partners Sanofi and Regeneron.

Monday's news focused on the antibody's impact on the rare disease homozygous familial hypercholesterolemia, known as HofH. The genetic disorder causes LCL levels to soar by the age of two. The TESLA trial in this patient population was a two-part Phase II/III study that included adult patients and adolescents under the age of 18.

Amgen said in a statement that the trial showed clinically meaningful and statistically significant drops in LDL-C levels at the 12-week mark.

Pursuit of this rare disease indication is one reason the drug has intrigued analysts who estimated in January—when Amgen released Phase III results of its GAUSS-2 trial—that the drug could reach $1 billion in sales by 2020 were it to launch in 2016.

Analysts forecast at the time sales of around $865 million for Sanofi and Regeneron's experimental contender, alirocumab.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...